Login to Your Account



For CNS Discovery Efforts, is Glass Half Full or Half Empty?

By Anette Breindl


Monday, January 31, 2011
Near-simultaneous recent announcements that London-based GlaxoSmithKline plc and AstraZeneca plc are dropping internal drug discovery efforts in various central nervous system (CNS) diseases has led to some talk of an overall big pharma retrenchment from those disorders.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription